DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Apadaz is a drug marketed by Kvk Tech Inc and is included in one NDA. There are five patents protecting this drug.
This drug has thirty-two patent family members in nineteen countries.
The generic ingredient in APADAZ is acetaminophen; benzhydrocodone hydrochloride. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetaminophen; benzhydrocodone hydrochloride profile page.
Apadaz was eligible for patent challenges on December 31st, 1968.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 22nd, 2031. This may change due to patent challenges or generic licensing.
Generic Entry Opportunity Date for APADAZ
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for APADAZ
|Acetaminophen / benzhydrocodone hydrochloride|
|Acetaminophen and benzhydrocodone hydrochloride|
|Acetaminophen mixture with benzhydrocodone hydrochloride|
|Country||Patent Number||Estimated Expiration|
|South Korea||101795330||Start Trial|
|World Intellectual Property Organization (WIPO)||2011002991||Start Trial|
|New Zealand||597235||Start Trial|
|South Korea||20180081176||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|